OXFORD, United Kingdom, 3 November 2026 – The canine cancer therapeutics company CaniVax today announced that it had initiated its first clinical study on its lead cancer therapeutic, CaniVive™, in canine patients suffering from late-stage metastatic cancer. The study involves a series of leading veterinary centres and university veterinary schools within the United Kingdom. Patients treated with CaniVive™ have advanced disease that is unresponsive to any alternative therapy.
Announcing the new clinical studies, CaniVax Chief Operations Officer Dr Zheng commented, “There remains a substantial unmet clinical need for dogs with advanced cancer. Progressing CaniVive™ into clinical evaluation is an important step in our development programme. Our priority is to generate the evidence needed to assess its potential and guide further development. Alongside this work, we continue to develop our canine cancer vaccine programme, consistent with our broader strategy of translating advances in human oncology into new treatment options for dogs.”
Dr Zheng further commented, “Our focus is on disciplined execution of our development strategy: advancing our clinical programmes, addressing unmet needs in canine oncology and building long-term value for shareholders.”
Background on CaniVax:
CaniVax is a veterinary biopharmaceutical company developing new therapeutics for treating advanced cancer in dogs. CaniVax advances its proprietary products and platforms built on deep insights into canine cancer biology and multi-omics gene and protein expression technologies, complemented by deep-learning algorithms, to identify cancers that are responsive to treatment. The company’s scientific and clinical strategy is focussed on educating the dog’s immune system to recognise and destroy tumour cells. The company is located in Oxford, United Kingdom.
Background on canine cancer:
Approximately one in four dogs will develop cancer during their lifetime, with risk increasing significantly with age. Common canine cancers include lymphoma, melanoma, mast cell tumours and osteosarcoma. Despite advances in veterinary care, significant unmet clinical needs persist across many of these cancers.
The global veterinary oncology market continues to expand, supported by rising cancer prevalence in ageing pet populations and increased spending on veterinary care. Industry estimates value the market at several billion United States dollars in the mid-2020s, with a compound annual growth rate of approximately 12%. Continued growth is projected across international markets, reflecting the global scope of veterinary oncology.
Download the Press Release here
For further information, contact:
See: www.canivax.com/news